Logo image of BCYC

BICYCLE THERAPEUTICS PLC-ADR (BCYC) Stock Fundamental Analysis

NASDAQ:BCYC - Nasdaq - US0887861088 - ADR - Currency: USD

7.39  -0.1 (-1.34%)

After market: 7.39 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to BCYC. BCYC was compared to 568 industry peers in the Biotechnology industry. While BCYC has a great health rating, there are worries on its profitability. BCYC is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BCYC had negative earnings in the past year.
BCYC had a negative operating cash flow in the past year.
BCYC had negative earnings in each of the past 5 years.
In the past 5 years BCYC always reported negative operating cash flow.
BCYC Yearly Net Income VS EBIT VS OCF VS FCFBCYC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

BCYC has a Return On Assets of -17.67%. This is amongst the best in the industry. BCYC outperforms 80.46% of its industry peers.
With an excellent Return On Equity value of -21.31%, BCYC belongs to the best of the industry, outperforming 85.92% of the companies in the same industry.
Industry RankSector Rank
ROA -17.67%
ROE -21.31%
ROIC N/A
ROA(3y)-25.15%
ROA(5y)-24.21%
ROE(3y)-37.21%
ROE(5y)-36.87%
ROIC(3y)N/A
ROIC(5y)N/A
BCYC Yearly ROA, ROE, ROICBCYC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCYC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCYC Yearly Profit, Operating, Gross MarginsBCYC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

7

2. Health

2.1 Basic Checks

BCYC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BCYC has an improved debt to assets ratio.
BCYC Yearly Shares OutstandingBCYC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
BCYC Yearly Total Debt VS Total AssetsBCYC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.27, we must say that BCYC is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.27, BCYC is doing good in the industry, outperforming 70.95% of the companies in the same industry.
BCYC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.27
ROIC/WACCN/A
WACC9.08%
BCYC Yearly LT Debt VS Equity VS FCFBCYC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 13.81 indicates that BCYC has no problem at all paying its short term obligations.
BCYC has a better Current ratio (13.81) than 87.85% of its industry peers.
BCYC has a Quick Ratio of 13.81. This indicates that BCYC is financially healthy and has no problem in meeting its short term obligations.
BCYC has a Quick ratio of 13.81. This is amongst the best in the industry. BCYC outperforms 87.85% of its industry peers.
Industry RankSector Rank
Current Ratio 13.81
Quick Ratio 13.81
BCYC Yearly Current Assets VS Current LiabilitesBCYC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

8

3. Growth

3.1 Past

BCYC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.50%, which is quite impressive.
The Revenue has grown by 30.74% in the past year. This is a very strong growth!
BCYC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.65% yearly.
EPS 1Y (TTM)42.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.31%
Revenue 1Y (TTM)30.74%
Revenue growth 3Y44.46%
Revenue growth 5Y20.65%
Sales Q2Q%-30.44%

3.2 Future

Based on estimates for the next years, BCYC will show a very strong growth in Earnings Per Share. The EPS will grow by 23.43% on average per year.
Based on estimates for the next years, BCYC will show a very strong growth in Revenue. The Revenue will grow by 69.90% on average per year.
EPS Next Y-19.01%
EPS Next 2Y-19.08%
EPS Next 3Y-6.66%
EPS Next 5Y23.43%
Revenue Next Year-15.15%
Revenue Next 2Y-7.76%
Revenue Next 3Y37.38%
Revenue Next 5Y69.9%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BCYC Yearly Revenue VS EstimatesBCYC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
BCYC Yearly EPS VS EstimatesBCYC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCYC. In the last year negative earnings were reported.
Also next year BCYC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCYC Price Earnings VS Forward Price EarningsBCYC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCYC Per share dataBCYC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as BCYC's earnings are expected to decrease with -6.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.08%
EPS Next 3Y-6.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCYC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BICYCLE THERAPEUTICS PLC-ADR

NASDAQ:BCYC (4/17/2025, 8:03:36 PM)

After market: 7.39 0 (0%)

7.39

-0.1 (-1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2025-02-25/bmo
Earnings (Next)04-30 2025-04-30/bmo
Inst Owners92.37%
Inst Owner Change0%
Ins Owners1.99%
Ins Owner Change0%
Market Cap511.41M
Analysts82
Price Target30.18 (308.39%)
Short Float %9.06%
Short Ratio13.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.78%
Min EPS beat(2)6.37%
Max EPS beat(2)7.19%
EPS beat(4)4
Avg EPS beat(4)23.99%
Min EPS beat(4)6.37%
Max EPS beat(4)51.12%
EPS beat(8)5
Avg EPS beat(8)9.08%
EPS beat(12)6
Avg EPS beat(12)2.95%
EPS beat(16)8
Avg EPS beat(16)2.41%
Revenue beat(2)0
Avg Revenue beat(2)-47.36%
Min Revenue beat(2)-61.63%
Max Revenue beat(2)-33.08%
Revenue beat(4)2
Avg Revenue beat(4)42.92%
Min Revenue beat(4)-61.63%
Max Revenue beat(4)217.56%
Revenue beat(8)4
Avg Revenue beat(8)31.55%
Revenue beat(12)5
Avg Revenue beat(12)15.74%
Revenue beat(16)5
Avg Revenue beat(16)8.03%
PT rev (1m)0%
PT rev (3m)-11.33%
EPS NQ rev (1m)-0.33%
EPS NQ rev (3m)1.14%
EPS NY rev (1m)3.18%
EPS NY rev (3m)2.57%
Revenue NQ rev (1m)-4.76%
Revenue NQ rev (3m)24.51%
Revenue NY rev (1m)1.34%
Revenue NY rev (3m)4.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.5
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 0.64
EV/EBITDA N/A
EPS(TTM)-2.95
EYN/A
EPS(NY)-3.51
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0.51
BVpS11.46
TBVpS11.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.67%
ROE -21.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.15%
ROA(5y)-24.21%
ROE(3y)-37.21%
ROE(5y)-36.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.21%
Cap/Sales 3.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.81
Quick Ratio 13.81
Altman-Z 1.27
F-Score5
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)192.2%
Cap/Depr(5y)162.86%
Cap/Sales(3y)48.56%
Cap/Sales(5y)34.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.31%
EPS Next Y-19.01%
EPS Next 2Y-19.08%
EPS Next 3Y-6.66%
EPS Next 5Y23.43%
Revenue 1Y (TTM)30.74%
Revenue growth 3Y44.46%
Revenue growth 5Y20.65%
Sales Q2Q%-30.44%
Revenue Next Year-15.15%
Revenue Next 2Y-7.76%
Revenue Next 3Y37.38%
Revenue Next 5Y69.9%
EBIT growth 1Y-10.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.93%
EBIT Next 3Y-12.54%
EBIT Next 5YN/A
FCF growth 1Y-161.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-171.7%
OCF growth 3YN/A
OCF growth 5YN/A